Hinrich Gronemeyer distinguished for his work on cancer
Sept. 14, 2015
On September 14th in Paris, Hinrich Gronemeyer received the Duquesne prize from the Ligue contre le cancer, a distinction which has been awarded for past and recent discoveries, which are relevant for the understanding of signal transduction and of global regulatory principles that can be deregulated in cancer. In addition to the basic science studies, the team of Hinrich Gronemeyer has developed several novel paradigms for cancer therapy.
Following last years laureate Hugues de Thé (Inserm, Collège de France), Hinrich Gronemeyer received the René and Andrée Duquesne prize from the Ligue contre le cancer in 2015; the Prize comprises a medal and 75,000 euros.
The Duquesne Prize is a prestigious award that distinguishes studies that led to a major advance or particularly promising results in the field of oncology.
At the head of a team of fourteen people, labelled by the Ligue contre le cancer since 2006, Hinrich Gronemeyer and his team have provide important contributions to the understanding of the mechanisms of (de)regulation of gene expression programs in normal and cancer cells, provided therapeutically important insight into cancer cell-selective apoptosis and established a link between cancer and aging, and discovered novel regulatory paradigms.
Hinrich Gronemeyer already receives the Excellence Award from INSERM (2010-2017) ; he got the European Medal of the Endocrine Society (1996) and the Scientific Prize of the French Society of Endocrinology (1991). He is a member of the European Molecular Biology Organization (EMBO) since 1995. Moreover, he is part of the list of the 3,200 most influential scientists in the world, established by Thomson Reuters. His research is relevant to clinical research; he received a hospital-INSERM interface contract for 2005-2009 and a hospital contract for translational research for the period 2010-2013.